What is the definition of bone marrow transplant (BMT) survival rate?
The BMT survival rate measure is defined as the percentage of patients who received blood-forming (hematopoietic) stem cell transplants who have survived over the indicated period of time. The data is further broken down by the stem cell source: either from the patient (autologous) or from another donor (allogeneic).
Why do we measure BMT survival rates?
At the Center for Cancer and Blood Disorders at Children's Hospital Colorado, we measure BMT transplant survival rates to better understand the effectiveness of treatments used to improve patient outcomes. This is all part of our efforts to provide the best care for babies, kids and adolescents with cancer and noncancerous blood diseases.
How does Children's Colorado compare to international BMT survival rates?
To understand our BMT Program's performance versus international standards, we look at the Center for International Blood and Marrow Transplant Research (CIBMTR) analysis of survival rates, taking into account key patient variables such as age, disease and donor type. For the years of 2008, 2009 and 2010 (the most recent comparative data available), our actual one-year post-BMT patient survival was 85.1%, which is superior to the expected survival rate of 68.6%.
What does this data mean?
The National Marrow Donor Program performed an analysis based on transplants performed from Jan. 1, 2007 through Dec. 31, 2009 using unrelated donors and transplants performed from Jan. 1, 2008 through Dec. 31, 2009 using related donors. It only included patients who underwent their first allogeneic transplant (from another donor) within these time periods and who had at least 100-day follow-up.
Children's Colorado reported survival status data for 50 patients. The actual one-year survival of these patients was 85.1%. The predicted one-year survival was 68.6%. This means that the CCBD at Children's Colorado had results/survival rates above the predicted range, placing us in the upper 6% of U.S. transplant centers.
The graph below shows our bone marrow transplants by type: overall, from the patient (autologous) and from another donor (allogeneic).
How has the Pediatric BMT Program at Children's Colorado been able to improve survival rates?
We have been able to improve BMT patient survival through participation in local, national and international clinical trials evaluating new approaches to pediatric BMT. In addition, since 2000, our program has had a comprehensive quality assurance (QA) program that looks at performance on an ongoing basis.
The BMT Quality Assurance Program at the University of Colorado Anschutz Medical Campus is a collaboration between the Adult BMT Program at the University of Colorado Hospital and the Pediatric BMT Program at Children's Colorado. This effort, which is led by our Pediatric BMT Program, was developed and continues to operate in accordance with national guidelines established by the Foundation for Accreditation of Cellular Therapy (FACT).
What is the source of this data?
The Center for Cancer and Blood Disorders at Children's Colorado maintains internal BMT patient data. All BMT patient data is carefully vetted by our BMT medical staff and data team.
Do we have a national benchmark?
The Center for International Blood and Marrow Transplant Research (CIBMTR) collects outcome data from hundreds of transplant centers throughout North America and the world. This data is used to create predictions of survival outcomes for each individual center's patients. This measure is an accepted benchmark standard monitored by the bone marrow transplant community.
See how we compare to other centers around the world, according to the National Marrow Donor Program.
How often will this data be updated?
The Pediatric BMT Program at Children's Colorado, through our local FACT QA Program, updates and analyzes pediatric and adult BMT survival rates data twice annually in addition to compiling a comprehensive annual performance report. We will report this information on a regular basis on this website.
Learn more about our Bone Marrow Transplant Program.